Ovoca Gold PLC

Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. Show More...

  • Website https://ovocabio.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.15 GBX
  • Last Updated 07-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2009-12 2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM
    Earnings Per Share EUR 0.02 -0.03 0.05 -0.03 -0.17 -0.08 -0.03 -0.010 -0.03 -0.03
    Dividends EUR
    Payout Ratio % *
    Shares Mil 91.0 95.0 94.0 89.0 87.0 87.0 82.0 82.0 82.0 82.0 58.0
    Book Value Per Share * GBP 0.55 0.51 0.45 0.33 0.23 0.2 0.29 0.24 0.2 0.23
    Free Cash Flow Per Share * GBP -0.09 -0.1 -0.04 -0.07 -0.02 0.08 -0.02 -0.010
    Return on Assets % 4.65 -5.82 6.4 -3.61 -33.37 -25.96 -9.99 -4.22 -1.65 -10.65 -10.0
    Financial Leverage (Average) 1.04 1.23 1.26 1.24 1.09 1.01 1.01 1.01 1.0 1.18 1.08
    Return on Equity % 4.83 -6.67 7.98 -4.52 -39.72 -27.44 -10.12 -4.27 -1.66 -11.53 -10.44
    Return on Invested Capital % 4.23 -7.87 7.01 -5.68 -43.85 -29.7 -10.08 -5.18 -3.63 -10.97 -10.48
    Interest Coverage 290.5 7.88 204.0 -88.24 -829.63 -221.2 -86.18 -33.64 -198.6 -206.1
    Current Ratio 12.92 4.11 9.88 2.37 5.92 27.77 30.21 31.48 121.59 2.28 28.57
    Quick Ratio 12.92 4.06 9.84 1.36 5.72 27.43 29.81 31.06 120.63 1.67 23.52
    Debt/Equity